Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease

Verve Therapeutics

Status: Invitation-only

Conditions: Atherosclerotic Cardiovascular Disease; Hypercholesterolemia; Heterozygous Familial Hypercholesterolemia

Study type: Observational

Funder types: Industry

Identifiers

NCT06112327

LTF-001

Details and patient eligibility

About

LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.

Enrollment: 116 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

1. A participant has completed or discontinued from a Verve sponsored clinical study in which they received at least one dose of study drug.
2. A participant has provided informed consent for LTF-001.

Exclusion Criteria: N/A